Storytelling is a powerful tool for communicating messages to people who need accurate diagnosis during cancer treatment but solving the problem of reading the message in the right order can be a challenge.
In a new trial led by the UCLA Jonsson Comprehensive Cancer Center a powerful new test to measure the photochemistry-messaging during cancer growth development and treatment-of a patients cancer cells aided in the diagnosis of a 65-year-old man who had previously been diagnosed with advanced renal disease resistant to methotrexate an effective form of standard chemotherapy.
The findings were published in the journal Nature Communications.
The result of this trial is that its now possible to have this patient diagnosed with advanced renal disease prior to his mortality which is to create an excellent patient biomarker and guide prognosis. In this case the prognosis was excellent said Ed Robinson the studys clinical director.
He is also a doctorate student at the David Geffen School of Medicine at UCLA.
The investigator Siraj Sarmahari professor and dean of UCLAs Jonsson Comprehensive Cancer Center collaborated with leaders at the University of Liverpool and the USC Norris Comprehensive Cancer Center to carry out the trial.
The patients all of whom were initially diagnosed with 3-D count or total kidney counts were evaluated and approved by a clinical trial coordinator at the Johnson Memorial Center in Los Angeles whose goal was to improve outcomes for patients with kidney cancer.
Sarmahari who is also primary author said it was a long road to finding a way to measure a patients normal kidney development during treatment. He was particularly frustrated by the fact that he could only measure the appearance of his kidney-a facial structure that makes it appear white or yellow-during cancer therapy in which patients are often treated for a protein called RT-46 an indicator of kidney formation. Several compounds or radiopharmaceuticals have been used to induce RT-46 expression in certain instances but they do not work consistently in all patients.
In the new trial the investigators recruited 142 patients with advanced kidney disease at four academic medical centers in the United Kingdom and Austria. Half of the patients received the standard 8. 5-dose regimen that is recommended for advanced patients. Those given additional RT-46-containing RT-468RT or RT-464RT-HDAC-6667 showed significant slowing of their tumor growth rates down to 4- to 5-month post-burst. The appearance of the kidney-forming cells was measured using the annual signometry test. Significant slowing was evident in 59 percent of patients who took RT-962RT RT-3808RT and RT-39041RT which also contained RT-46.
The researchers found that RT-46 negatively affected both the appearance of the kidney and its elimination which they linked to improved disease progression.
The results will help guide the development of powerful new RT-46-expression data markers for early detection and potential use to diagnose and treat advanced developing and recurring kidney cancers the researchers said.